Last reviewed · How we verify
AZD1722 free base tablet
AZD1722 free base tablet is a Small molecule drug developed by Ardelyx. It is currently in Phase 1 development.
AZD1722 free base tablet is a small molecule medication. It is being studied in a Phase I clinical trial to evaluate its pharmacodynamics in healthy subjects, with and without food.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AZD1722 free base tablet |
|---|---|
| Sponsor | Ardelyx |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects (PHASE1)
- A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD1722 free base tablet CI brief — competitive landscape report
- AZD1722 free base tablet updates RSS · CI watch RSS
- Ardelyx portfolio CI
Frequently asked questions about AZD1722 free base tablet
What is AZD1722 free base tablet?
Who makes AZD1722 free base tablet?
What development phase is AZD1722 free base tablet in?
Related
- Manufacturer: Ardelyx — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing